Immunomedics (IMMU) Misses Q1 EPS by 86c

Immunomedics (NASDAQ: IMMU) reported Q1 EPS of ($0.97), $0.86 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $690.49 million, versus $741.81 million reported last year.

For earnings history and earnings-related data on Immunomedics (IMMU) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Vireo Growth completes acquisition of C21 Investments
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance